Comprehensive Report on LY-3537031: An Investigational Dual GIPR/GLP-1R Agonist

1. Executive Summary of LY-3537031

LY-3537031 is an investigational synthetic peptide currently under development by Eli Lilly and Company, positioned within the therapeutic area of endocrinology and metabolic diseases, with a primary focus on obesity.[1] The compound functions as a dual agonist for the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R).[1] This mechanism of action is well-established within Eli Lilly's portfolio, notably with the successful drug tirzepatide. LY-3537031 is administered subcutaneously and is recognized as a New Molecular Entity (NME), a designation that underscores its novelty and potential for market exclusivity upon approval.[2]

The clinical development program for LY-3537031 is in Phase 1. A single ascending dose (SAD) study, NCT04648865, conducted in healthy Japanese volunteers, has been completed.[1] A more extensive multiple ascending dose (MAD) study, NCT06606106, is currently recruiting participants, including overweight and obese individuals, as well as healthy volunteers from diverse ethnic backgrounds, including Japanese and Chinese cohorts.[1] This ongoing trial aims to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of LY-3537031, including its effects on body weight and gastric emptying. The development of LY-3537031, identified in Eli Lilly's pipeline as "GIP/GLP-1 Coagonist III" [6], signifies a continued strategic investment by the company in leveraging dual incretin agonism to address the significant unmet medical needs in obesity and related metabolic conditions.

2. Introduction to LY-3537031

Background and Rationale for Development in Obesity and Metabolic Diseases

The escalating global prevalence of obesity and its associated metabolic comorbidities, such as type 2 diabetes and cardiovascular disease, presents a substantial public health challenge and underscores the urgent need for effective and well-tolerated therapeutic interventions.[7] In recent years, incretin-based therapies have emerged as a cornerstone in the management of these conditions. These therapies primarily target receptors for gut hormones like glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which play crucial roles in glucose homeostasis and energy balance.[7]

The development of LY-3537031 is built upon the significant clinical success observed with agents that modulate these pathways. In particular, dual agonism at both GIPR and GLP-1R has demonstrated the potential for superior glycemic control and more substantial weight reduction compared to therapies targeting only GLP-1R.[8] Eli Lilly's tirzepatide (marketed as Mounjaro for type 2 diabetes and Zepbound for obesity) serves as a prime example of the efficacy achievable with this dual-agonist approach.[8] Furthermore, Eli Lilly's Q1 2025 earnings report highlighted the positive developments for orforglipron, an oral GLP-1 agonist, further emphasizing the company's strong commitment and success in advancing innovative treatments for metabolic diseases.[6] LY-3537031 appears to be an effort to further capitalize on or refine the therapeutic benefits of dual GIPR/GLP-1R agonism.

Originator: Eli Lilly & Co.

Eli Lilly and Company is the originator and the active organization spearheading the development of LY-3537031.[1] The company has a long-standing history and a prominent leadership position in the fields of diabetes and obesity research and treatment. Its portfolio includes several blockbuster medications, and its pipeline is rich with novel candidates targeting various aspects of metabolic dysfunction.[6] This extensive experience and proven track record in developing and commercializing successful metabolic therapies provide a strong foundation and strategic context for the advancement of LY-3537031.

The internal designation of LY-3537031 as "GIP/GLP-1 Coagonist III" within Eli Lilly's pipeline documentation is particularly noteworthy.[6] This nomenclature strongly suggests that LY-3537031 is not an isolated endeavor but rather a component of a broader, evolving program focused on GIP/GLP-1 co-agonism. Pharmaceutical companies, especially leaders in a therapeutic field like Eli Lilly, often pursue the development of multiple compounds within the same mechanistic class. This strategy allows for the exploration of molecules with potentially refined characteristics. The "III" designation implies that LY-3537031 may be a third-generation compound or a distinct iteration following earlier GIP/GLP-1 co-agonists developed by the company, including the highly successful tirzepatide. Such iterative development aims to achieve potential advantages over existing agents, which could manifest as enhanced efficacy, an improved safety or tolerability profile (particularly concerning gastrointestinal side effects common to this class), more convenient pharmacokinetic properties (e.g., optimized for less frequent dosing or a different delivery method), or superior manufacturing characteristics. Therefore, LY-3537031 likely represents a strategic effort by Eli Lilly to expand, improve upon, or differentiate its GIP/GLP-1 co-agonist portfolio, aiming to address a wider range of patient needs or to secure a competitive edge in the dynamic metabolic disease market.

3. Pharmacological Profile

The fundamental pharmacological and developmental characteristics of LY-3537031, based on available information, are consolidated in Table 1.

Table 1: Key Characteristics of LY-3537031

Attribute	Description	Source(s)
Drug Name	LY-3537031	User Query
Alternative Names	ly-3537031, ly 3537031, ly3537031	2
Originator	Eli Lilly & Co.	1
Drug Type/Modality	Synthetic peptide, Peptide/Protein	1
Mechanism of Action	GIPR agonist, GLP-1R agonist	1
Receptor Targets	GIPR (Gastric inhibitory polypeptide receptor), GLP-1R (Glucagon-like peptide 1 receptor)	1
Route of Administration	Subcutaneous (SC)	2
Primary Therapeutic Area	Endocrinology and Metabolic Disease	1
Primary Indication	Obesity	1
Regulatory Status	New Molecular Entity (NME)	3

This table serves as a foundational reference, summarizing the core identity of LY-3537031. Such a consolidation is vital for an expert audience requiring a rapid yet thorough understanding of the drug's basic properties before delving into more nuanced aspects of its development and potential.

Chemical Nature and Modality

LY-3537031 is characterized as a synthetic peptide [1] and falls under the modality of a peptide/protein therapeutic.[2] This classification aligns with the nature of other prominent incretin mimetics, such as tirzepatide, semaglutide, and liraglutide, which are also peptide-based molecules designed to interact with G protein-coupled receptors. The specific amino acid sequence, which dictates the peptide's structure, receptor interaction, and pharmacokinetic properties, has not been publicly disclosed in the available research materials.

Mechanism of Action: Dual GIPR and GLP-1R Agonism

The primary mechanism of action for LY-3537031 is agonism at both the Gastric Inhibitory Polypeptide Receptor (GIPR) and the Glucagon-Like Peptide-1 Receptor (GLP-1R).[1] This dual agonism is intended to harness the synergistic effects of both incretin pathways to achieve enhanced metabolic benefits.

It is pertinent to note a discrepancy in the reporting of LY-3537031's mechanism. While sources such as Synapse [1] and Ozmosi [2] clearly identify the mechanism as dual GIPR/GLP-1R agonism, AdisInsight has reported an "Undefined mechanism" for the compound.[3] This variation in reporting is not uncommon for investigational drugs in early stages of development. It can arise from differences in database update cycles, the timing of information release by the sponsor, or a more conservative approach by some databases pending fuller public disclosure. However, considering Eli Lilly's profound expertise and established success with tirzepatide, a GIP/GLP-1R dual agonist [8], and the internal designation of LY-3537031 as "GIP/GLP-1 Coagonist III" [6], the dual agonism mechanism is highly plausible and represents the most consistent interpretation of the available evidence. The "undefined" status in some databases likely reflects an information lag rather than a fundamental uncertainty about the drug's intended mechanism.

The specific binding affinities of LY-3537031 for GIPR and GLP-1R, its potency at each receptor, and the precise balance of its activity (e.g., whether it favors GIPR, GLP-1R, or exhibits balanced agonism) are not detailed in the provided information. For context, tirzepatide is characterized by an "imbalanced" mechanism, demonstrating greater engagement with the GIP receptor, and exhibits biased agonism at the GLP-1 receptor, favoring cAMP generation over β-arrestin recruitment.[8] These specific molecular interactions are believed to contribute to its overall efficacy profile. It is conceivable that LY-3537031 has been engineered with a similarly tailored GIPR/GLP-1R activity profile to optimize its therapeutic effects.

Based on the known signaling pathways of GIPR and GLP-1R activation, LY-3537031 is expected to mediate its effects through several intracellular mechanisms. Activation of these G protein-coupled receptors typically leads to an increase in intracellular cyclic adenosine monophosphate (cAMP) and subsequent activation of protein kinase A (PKA).[7] These signaling events, in turn, influence a range of physiological processes critical to metabolic regulation. GIPR activation is known to promote insulin secretion from pancreatic β-cells and also plays a role in adipocyte metabolism and fat storage.[7] GLP-1R activation similarly stimulates glucose-dependent insulin secretion, concurrently suppresses glucagon release from pancreatic α-cells, slows gastric emptying (which contributes to satiety), and reduces appetite through central nervous system effects.[11] The combined and potentially synergistic actions resulting from dual agonism at these receptors are anticipated to lead to significant weight loss and improvements in overall metabolic health in individuals with obesity.

Route of Administration

LY-3537031 is designed for subcutaneous (SC) administration.[1] This route is standard for many peptide-based therapeutics, particularly in the incretin class, as it allows for direct absorption into systemic circulation while bypassing first-pass metabolism in the liver, which can degrade peptide drugs if administered orally without specialized formulation technologies.

4. Clinical Development Program

LY-3537031 is currently in Phase 1 of clinical development.[1] The program comprises at least two distinct studies designed to evaluate its initial safety, tolerability, pharmacokinetics, and pharmacodynamics. A summary of these trials is presented in Table 2.

Table 2: Summary of Clinical Trials for LY-3537031

Trial Identifier	Phase	Study Title	Status	Key Objectives/Primary Outcome(s)	Participant Population(s)	Key Secondary Outcome(s)	Start Date	Estimated Primary Completion
NCT04648865	1	A Single-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3537031 in Healthy Participants	Completed	Safety and tolerability of single doses; Pharmacokinetics	Healthy Japanese volunteers (N=40, aged 20-65 yrs, BMI 19-35 kg/m²)	Pharmacokinetics (Cmax, AUC)	Dec 2020	Not specified (Completed)
NCT06606106	1	A Multiple-Ascending Dose Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of LY3537031 in Overweight and Obese Participants and Healthy Volunteers	Recruiting	Safety and tolerability (Number of participants with TEAEs, SAEs, AEs related to study drug)	Part A: Overweight/obese (BMI 27-45 kg/m²); Part B: Healthy (BMI 22-26.9 kg/m²); Part C: Healthy Japanese & Chinese. Total ~230, aged 22-65 yrs.	PK (Cmax, AUC); PD (Body weight, Fasting Glucose, OGTT, Insulin, C-peptide, Gastric emptying via acetaminophen)	Sep 5, 2024	Jul 1, 2026

This table offers a structured comparison of the two known clinical trials for LY-3537031, facilitating an understanding of their respective designs, objectives, target populations, and developmental timelines. Such a comparison is crucial for tracking the drug's progression through early clinical evaluation.

Phase 1 Single Ascending Dose (SAD) Study: NCT04648865

The initial clinical evaluation of LY-3537031 was conducted under the trial identifier NCT04648865, titled "A Single-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3537031 in Healthy Participants".[1] This study was a Phase 1, randomized, double-blind, placebo-controlled trial designed to assess the effects of single ascending doses of the investigational drug.[1]

The primary objective was to evaluate the safety and tolerability of LY-3537031 when administered as a single dose.[1] The study enrolled 40 healthy volunteers in Japan, encompassing males and non-childbearing potential females aged between 20 and 65 years, with a Body Mass Index (BMI) ranging from 19 to 35 kg/m² and a minimum body weight of 54 kg.[1] Secondary objectives focused on characterizing the pharmacokinetic profile of LY-3537031, specifically how much of the drug enters the bloodstream (e.g., Cmax) and how long the body takes to eliminate it (e.g., AUC, half-life).[1] Participants received a single subcutaneous injection of either LY-3537031 at one of the planned dose levels or a placebo.[1] The specific dose levels investigated in this SAD study are not disclosed in the available documentation.

The NCT04648865 study commenced in December 2020 and has since been completed.[1] However, detailed results regarding the safety, tolerability, or pharmacokinetic findings from this trial are not publicly available in the provided research snippets. While some database entries suggest associated clinical results may be available through restricted access [1], these specific data points are not present in the accessible material. The direct link to ClinicalTrials.gov for this study [23] was inaccessible at the time of this review.

The decision to conduct this first-in-human, single ascending dose study exclusively in Japanese healthy volunteers represents a noteworthy strategic element in the early development of LY-3537031.[1] While many SAD studies enroll a general healthy population, focusing on a specific ethnic group from the outset provides early, valuable data on the drug's behavior (pharmacokinetics and safety) within that demographic. This approach can be particularly important if ethnic differences in drug metabolism, receptor sensitivity, or general physiological responses are known or anticipated for the drug class. The data generated from Japanese participants can directly inform dose selection and study design for subsequent trials intended for Japan or other East Asian countries, potentially streamlining and accelerating the drug's development and regulatory pathway in these significant markets.

Phase 1 Multiple Ascending Dose (MAD) Study: NCT06606106

Following the SAD study, Eli Lilly initiated a more extensive Phase 1 trial, NCT06606106, titled "A Multiple-Ascending Dose Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of LY3537031 in Overweight and Obese Participants and Healthy Volunteers".[1] This study is currently recruiting participants. It is designed as a randomized, double-blind, placebo-controlled trial involving multiple ascending doses of LY-3537031 and is structured into three distinct parts (Part A, Part B, and Part C) to evaluate the drug in different populations.[1]

• Part A will enroll participants who are overweight or obese, defined by a BMI between 27.0 and 45.0 kg/m². This cohort is critical as it represents the target patient population for an obesity therapeutic.[1]
• Part B will include healthy volunteers with a BMI between 22.0 and 26.9 kg/m².[1]
• Part C is specifically designed for healthy volunteers of Japanese and Chinese ethnicity, continuing the focus on generating data in East Asian populations.[1] The study aims to enroll approximately 230 participants in total, aged between 22 and 65 years.[21]

The primary outcome measure for NCT06606106 is the safety and tolerability of LY3537031, assessed by the number of participants experiencing one or more treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events considered by the investigator to be related to study drug administration, monitored for up to 56 weeks.[1]

Secondary outcome measures are comprehensive and cover both pharmacokinetic and pharmacodynamic parameters, evaluated from predose on Day 1 through Week 56 [1]:

• Pharmacokinetics (PK): Maximum plasma concentration (Cmax) and Area Under the plasma concentration-time Curve (AUC) of LY3537031.
• Pharmacodynamics (PD):
• Change from baseline in body weight.
• Change from baseline in fasting glucose levels.
• Change from baseline in Oral Glucose Tolerance Test (OGTT) results, including the AUC of glucose.
• Change from baseline in insulin levels.
• Change from baseline in Connecting Peptide (C-peptide) levels.
• Assessment of gastric emptying, evaluated by the change from baseline in Cmax, AUC, and time to peak drug concentration (Tmax) of co-administered acetaminophen.

Participants will receive multiple ascending doses of LY-3537031 or placebo via subcutaneous administration. The specific dose levels or the dose escalation scheme are not detailed in the available snippets. Direct links to ClinicalTrials.gov for more detailed protocol information [21] were inaccessible.

The NCT06606106 trial is actively recruiting participants.[1] It officially started on September 5, 2024.[1] The estimated primary completion date and study completion date were updated on April 18, 2025, and are now both set for July 1, 2026, revised from an earlier estimate of July 1, 2025.[5] The total duration of participation for an individual in the study is reported with some variability across sources, ranging from approximately 20 weeks [1] to 48 weeks [22] or 56 weeks.[21] The 56-week duration, cited on the sponsor's trial information page, likely represents the most accurate overall commitment, including any follow-up periods.

The design of the NCT06606106 study, particularly its inclusion of extensive pharmacodynamic endpoints in both the target overweight/obese population and healthy volunteers (including dedicated Japanese and Chinese cohorts), is a significant aspect of the early development strategy.[1] Phase 1 MAD studies often prioritize safety and pharmacokinetics. However, by incorporating measures such as body weight change, glucose metabolism markers (fasting glucose, OGTT, insulin, C-peptide), and gastric emptying from this early stage, Eli Lilly aims to gather preliminary signals of the drug's metabolic effects. This comprehensive early data package, which also allows for the assessment of potential ethnic differences in drug response beyond just PK, can substantially accelerate internal decision-making processes for advancing to Phase 2 development and will be instrumental in shaping the global clinical development strategy.

Furthermore, the specific inclusion of an acetaminophen absorption test to assess gastric emptying is a critical component of the NCT06606106 trial design.[1] Delayed gastric emptying is a well-recognized mechanism of action for GLP-1 receptor agonists and related compounds, contributing to increased satiety and subsequent weight loss.[11] However, this physiological effect also carries implications for the absorption of concomitantly administered oral medications, posing a potential risk for drug-drug interactions (DDIs). Additionally, delayed gastric emptying can contribute to the gastrointestinal side effects commonly observed with this class of drugs. Quantifying the extent and duration of LY-3537031's effect on gastric emptying early in its development will be vital for predicting its DDI liability, understanding its tolerability profile, and guiding recommendations for its use with other medications in later phases of development and, if approved, in clinical practice.

Dose Escalation and Range Finding

Both the completed SAD study (NCT04648865) and the ongoing MAD study (NCT06606106) employ dose-escalation methodologies.[1] The fundamental objective of Phase 1 dose-escalation trials is to systematically increase the dose of the investigational drug administered to successive cohorts of participants. This process allows researchers to carefully monitor for safety and tolerability, identify any dose-limiting toxicities (DLTs), and ultimately determine the maximum tolerated dose (MTD) or the recommended Phase 2 dose (RP2D).[27] The MTD is generally defined as the highest dose that does not cause unacceptable toxicity, while the RP2D is the dose selected for further efficacy testing in Phase 2 trials, based on an integrated assessment of safety, tolerability, PK, and any available PD data.

The specific dose levels of LY-3537031 being tested or planned for these Phase 1 studies are not provided in the publicly accessible research snippets. This lack of detailed dosage information is a common practice in the early stages of pharmaceutical development. Companies often maintain confidentiality regarding exact dose ranges and escalation schemes for proprietary and competitive reasons. Such information typically becomes publicly available at later stages of development, often through presentations at scientific conferences or in peer-reviewed publications, once a clearer understanding of the drug's safety and tolerability across a range of doses has been established and key dosing decisions for subsequent trials have been made.

5. Regulatory and Intellectual Property Status

Regulatory Designations

LY-3537031 has been identified as a New Molecular Entity (NME).[3] This classification by regulatory authorities is significant because NMEs, upon successful clinical development and marketing approval, are typically granted periods of market exclusivity. This exclusivity protects the drug from generic competition for a defined timeframe, providing a crucial commercial incentive for the substantial investment required in pharmaceutical research and development.

Conversely, LY-3537031 does not hold Orphan Drug status.[3] Orphan Drug designation is granted to therapies intended for rare diseases or conditions. Given that obesity is a highly prevalent condition affecting a large global population, the absence of Orphan Drug status for LY-3537031 is consistent with its target indication.

Patent Landscape Overview

Information from Synapse indicates that there are "100 Patents (Medical) associated with LY-3537031".[1] While this suggests a potentially broad portfolio of intellectual property related to the compound or its therapeutic area, specific patent numbers or detailed claims directly covering the composition of matter, formulation, or methods of use for LY-3537031 are not explicitly provided in the reviewed snippets.

Eli Lilly and Company is known for establishing and defending a robust patent estate for its innovative medicines, particularly in the highly competitive field of incretin-based therapies. For instance, their drug tirzepatide (Mounjaro/Zepbound) is protected by numerous patents, as evidenced by ongoing litigation concerning compounded versions during periods of drug shortage [16] and publicly available patent information, such as US Patent 11,918,623 B2, which covers certain tirzepatide compositions.[29]

Considering that LY-3537031 is a New Molecular Entity emerging from Eli Lilly's significant research and development efforts in the GIP/GLP-1 co-agonist space, it is virtually certain that the compound is, or will be, protected by comprehensive patent applications. These patents would typically cover the novel peptide sequence itself, various pharmaceutical formulations containing LY-3537031, and its methods of use for treating obesity and potentially other metabolic disorders. The absence of specific patent details for LY-3537031 in the provided snippets is likely due to the early stage of development or the indexing limitations of the databases searched, rather than an absence of intellectual property protection. A strong IP position is fundamental to safeguarding the innovation and commercial potential of a novel therapeutic like LY-3537031.

6. Preclinical Data and Drug Interactions

Preclinical Data

The provided research materials do not contain specific preclinical data for LY-3537031. Information regarding its in vitro characteristics, such as binding affinities to GIPR and GLP-1R, receptor activation potency, or selectivity profiles, is not detailed. Similarly, results from in vivo studies in animal models of obesity or diabetes, which would typically precede human clinical trials to establish proof-of-concept for efficacy and initial safety, are not available in these snippets. Such preclinical data is essential for justifying the progression of a compound into Phase 1 clinical trials but is often kept proprietary by pharmaceutical companies during the early phases of development, with disclosure typically occurring later through scientific publications or regulatory submissions.

Drug Interactions

No dedicated clinical drug-drug interaction (DDI) studies for LY-3537031 are mentioned as having been completed or currently being underway in the provided information. However, the design of the ongoing Phase 1 MAD study (NCT06606106) includes an assessment of gastric emptying using the acetaminophen absorption test.[1] This is a key proactive step in evaluating a physiological effect known to be relevant to potential DDIs for this class of drugs.

Peptide-based GLP-1 receptor agonists, and by extension GIP/GLP-1 co-agonists, are generally considered to have a low potential for metabolic DDIs mediated by cytochrome P450 (CYP) enzymes.[11] This is because peptide drugs are typically metabolized through general protein catabolism by ubiquitous peptidases, rather than being substrates, inhibitors, or inducers of CYP enzymes, which are common mechanisms for small molecule drug interactions. The primary DDI concern for the GLP-1RA class relates to their effect on gastric emptying. By slowing the rate at which stomach contents are emptied into the small intestine, these agents can alter the rate and potentially the extent of absorption of co-administered oral medications.[11]

The inclusion of the acetaminophen absorption test in the Phase 1 MAD study (NCT06606106) for LY-3537031 is a clear indication that Eli Lilly is proactively investigating this key pharmacodynamic effect. Acetaminophen is often used as a probe drug to assess gastric emptying rate; a delay in its absorption (e.g., reduced Cmax, prolonged Tmax) when co-administered with LY-3537031 would suggest an impact on gastric motility. Characterizing this effect early in development is crucial. It will provide initial insights into the potential for LY-3537031 to interact with other oral drugs, inform the design of any formal DDI studies that may be required by regulatory agencies, and help in developing guidance for the co-administration of LY-3537031 with other medications should it progress to later stages of development and potential marketing. This early assessment demonstrates a considered approach to understanding a well-known characteristic of the drug class that has implications for both therapeutic action and interaction potential.

7. Strategic Context and Future Perspectives

Positioning within Eli Lilly's Incretin and Obesity/Diabetes Portfolio

LY-3537031, identified as "GIP/GLP-1 Coagonist III" in Eli Lilly's pipeline [6], is a component of the company's broad and industry-leading portfolio targeting metabolic diseases. This portfolio includes the highly successful dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro/Zepbound), the oral GLP-1 receptor agonist orforglipron, and other innovative mechanisms such as the triple GIP/GLP-1/glucagon receptor agonist retatrutide, and the activin receptor antibody bimagrumab.[6]

The development of another GIP/GLP-1 co-agonist alongside these other programs suggests a multifaceted strategy by Eli Lilly. The company appears to be exploring variations on the successful dual-agonist theme, potentially aiming to create compounds with differentiated profiles. These differentiations could relate to enhanced efficacy in terms of weight loss or glycemic control, an improved safety and tolerability profile (particularly concerning gastrointestinal side effects which are common with this class), a more favorable pharmacokinetic profile that might allow for less frequent dosing or alternative delivery systems (though current trials for LY-3537031 utilize subcutaneous administration, consistent with weekly injectables in this class), or specific benefits in patient subpopulations or in addressing particular comorbidities associated with obesity.

Potential Differentiation and Market Outlook

The therapeutic landscape for obesity is rapidly evolving and becoming increasingly competitive, with several highly effective GLP-1 receptor agonists and dual agonists already on the market or in late-stage development.[19] For LY-3537031 to achieve clinical and commercial success, it will need to demonstrate a clear and meaningful differentiation from these existing and emerging therapies, including those from Eli Lilly's own pipeline.

Potential avenues for differentiation for LY-3537031 could include:

• Superior Efficacy: Achieving even greater weight loss or more significant improvements in metabolic parameters than current standards of care.
• Enhanced Tolerability: A side effect profile that is more favorable, particularly a reduction in the incidence or severity of gastrointestinal adverse events (nausea, vomiting, diarrhea), which can limit compliance with current agents.
• Improved Patient Convenience: While currently administered subcutaneously, future developments could explore less frequent dosing regimens if its pharmacokinetic profile supports this, or alternative delivery methods.
• Benefits in Specific Comorbidities: Demonstrating particular efficacy in addressing obesity-related complications such as cardiovascular disease, non-alcoholic steatohepatitis (NASH), or chronic kidney disease.

The global market for effective and safe obesity treatments is substantial and continues to expand as the understanding of obesity as a chronic disease grows.[19] This large and underserved market offers significant commercial opportunities for new therapeutic agents that can provide demonstrable advantages over existing options.

Scientific Publications and Presentations

As of the information available, there are no specific scientific publications or conference presentations solely dedicated to LY-3537031.[3] Eli Lilly's recent scientific disclosures and presentations at major endocrinology and obesity conferences (such as ADA, EASD, ObesityWeek) in 2023, 2024, and early 2025 have predominantly focused on their later-stage assets like tirzepatide, orforglipron, and retatrutide. This is a typical pattern for pharmaceutical development, where detailed data for compounds in early Phase 1 trials are usually reserved for later disclosure, often after key go/no-go decisions have been made based on initial findings. It is anticipated that data from the NCT04648865 and NCT06606106 trials will be presented at future scientific meetings or published in peer-reviewed journals as the clinical program for LY-3537031 progresses and sufficient data accumulates.

8. Expert Analysis and Concluding Remarks

Summary of Key Attributes and Development Progress

LY-3537031 is an investigational synthetic peptide developed by Eli Lilly and Company, functioning as a dual agonist for the GIP and GLP-1 receptors. It is administered subcutaneously and is being evaluated for the treatment of obesity. Classified as a New Molecular Entity, LY-3537031 is currently in Phase 1 of clinical development. The program includes a completed single ascending dose (SAD) study (NCT04648865) conducted in healthy Japanese volunteers, which focused on initial safety, tolerability, and pharmacokinetics. An ongoing, more extensive multiple ascending dose (MAD) study (NCT06606106) is actively recruiting overweight and obese individuals, as well as healthy volunteers, including specific cohorts of Japanese and Chinese participants. This MAD study aims to further characterize the safety, tolerability, and pharmacokinetic profile of LY-3537031, and importantly, to gather early pharmacodynamic data on its effects on body weight, glucose metabolism, and gastric emptying.

Potential Strengths

Several factors contribute to the potential strengths of LY-3537031:

1. Validated Mechanism: The dual GIPR/GLP-1R agonist mechanism has been clinically validated by the success of tirzepatide, demonstrating high potential for efficacy in treating obesity and related metabolic disorders. LY-3537031 builds upon this established and promising therapeutic approach.
2. Experienced Developer: Eli Lilly and Company is a global leader in the development of therapies for diabetes and obesity, possessing extensive experience, resources, and a proven track record in navigating the complexities of incretin mimetic development and commercialization.
3. Robust Early Clinical Design: The clinical development program for LY-3537031 incorporates early assessment in diverse ethnic populations (including Japanese and Chinese participants in both SAD and MAD studies) and includes comprehensive pharmacodynamic evaluations (body weight, glycemic parameters, gastric emptying) in Phase 1. This approach may provide a richer early dataset, potentially streamlining global development pathways and informing later-phase trial designs more effectively.

Challenges and Unanswered Questions

Despite its potential, LY-3537031 faces several challenges and unanswered questions inherent to early-stage drug development in a competitive field:

1. Differentiation in a Crowded Market: The obesity therapeutic landscape is rapidly evolving with numerous effective agents available or in late-stage development, including from Eli Lilly's own pipeline. LY-3537031 will need to demonstrate a clear and clinically meaningful differentiation—be it in efficacy, safety, tolerability, patient convenience, or benefits in specific subpopulations—to establish a significant role.
2. Tolerability Profile: Gastrointestinal adverse events (such as nausea, vomiting, and diarrhea) are common with incretin-based therapies. Managing these and ensuring a favorable overall tolerability profile for LY-3537031 will be crucial for patient adherence and its ultimate clinical utility.
3. Undisclosed Molecular Characteristics: The specific amino acid sequence of LY-3537031 and its precise GIPR/GLP-1R binding affinities and activity balance remain undisclosed. This information is critical for a full assessment of its novelty and potential advantages compared to other dual agonists.
4. Long Development Timeline: As a Phase 1 compound, LY-3537031 is many years away from potential regulatory approval and market availability. Long-term safety and efficacy data from larger, longer-duration Phase 2 and Phase 3 trials will be required.

Concluding Thought

LY-3537031 represents a continued and strategically important investment by Eli Lilly and Company in the highly promising and rapidly advancing field of incretin-based therapies for obesity. Its development leverages a validated dual-agonist mechanism, and the early clinical program appears robust, with a commendable focus on comprehensive characterization across diverse populations. The progression of LY-3537031 and the future disclosure of data from the ongoing NCT06606106 trial, particularly regarding its pharmacodynamic effects and tolerability at various doses, will be critical in determining its potential role and competitive positioning within the next generation of treatments for obesity and metabolic diseases.

Works cited

1. LY-3537031 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed May 22, 2025, https://synapse.patsnap.com/drug/11e2d0de2db748f5a42d48fca827c71b
2. LY-3537031 Drug Profile - Ozmosi, accessed May 22, 2025, https://pryzm.ozmosi.com/product/21356
3. LY 3537031 - AdisInsight, accessed May 22, 2025, https://adisinsight.springer.com/drugs/800061348
4. A Study of LY3537031 in Healthy Participants - ClinicalTrials.Veeva, accessed May 22, 2025, https://ctv.veeva.com/study/a-study-of-ly3537031-in-healthy-participants
5. A Multiple-Ascending Dose Study to Investigate the Safety ..., accessed May 22, 2025, https://adisinsight.springer.com/trials/700376706
6. Untitled - Eli Lilly Investors, accessed May 22, 2025, https://investor.lilly.com/static-files/761fadb8-b911-46d5-85b3-8bac4e054d73
7. GIPR: the Crucial Regulator of Glucose and Lipid Metabolism in Diabetes and Obesity!, accessed May 22, 2025, https://www.cusabio.com/c-21126.html
8. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 ..., accessed May 22, 2025, https://pubmed.ncbi.nlm.nih.gov/32730231/
9. Tirzepatide, GIP(1-42) and GIP(1-30) display unique signaling profiles at two common GIP receptor variants, E354 and Q354 - Frontiers, accessed May 22, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1463313/full
10. GLP-1/GIP/glucagon tri-agonist(Eli Lilly & Co.) - Drug Targets, Indications, Patents - Synapse, accessed May 22, 2025, https://synapse-patsnap-com.libproxy1.nus.edu.sg/drug/765e79b5054942deacb3d8b66ad59637
11. A Comprehensive Review on the Pharmacokinetics and Drug−Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist - Dove Medical Press, accessed May 22, 2025, https://www.dovepress.com/a-comprehensive-review-on-the-pharmacokinetics-and-drugdrug-interactio-peer-reviewed-fulltext-article-DDDT
12. Shaping the Future: Innovations and Trends in Obesity Treatment - William Blair, accessed May 22, 2025, https://www.williamblair.com/-/media/downloads/eqr/2025/williamblair_shaping-the-future-innovations-and-trends-in-obesity-treatment.pdf
13. Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review | Published in Journal of Brown Hospital Medicine, accessed May 22, 2025, https://bhm.scholasticahq.com/article/132255-current-insights-advantages-and-challenges-of-small-molecule-glucagon-like-peptide-1-receptor-agonists-a-scoping-review
14. Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine - PR Newswire, accessed May 22, 2025, https://www.prnewswire.com/news-releases/zepbound-tirzepatide-showed-superior-weight-loss-over-wegovy-semaglutide-in-complete-surmount-5-results-published-in-the-new-england-journal-of-medicine-302451241.html
15. Lilly's Zepbound Secures “Superior Benefit-Risk Ratio” Over Novo's Wegovy - BioSpace, accessed May 22, 2025, https://www.biospace.com/drug-development/lillys-zepbound-secures-superior-benefit-risk-ratio-over-novos-wegovy
16. Will Novo Nordisk and Eli Lilly use their patents to block compounders for GLP-1 agonists?, accessed May 22, 2025, https://www.markmanadvisors.com/blog/2025/3/21/will-novo-nordisk-and-eli-lilly-use-their-patents-to-block-compounders-for-glp-1-agonists
17. Q4 2024 Lilly Presentation, accessed May 22, 2025, https://investor.lilly.com/static-files/09d156c0-f88d-420b-b5f1-1ed2b417461b
18. Lilly reports first-quarter 2025 financial results and highlights pipeline momentum, accessed May 22, 2025, https://www.prnewswire.com/news-releases/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum-302443401.html
19. Exploring The 2025 Obesity Drug Pipeline | PSG - Pharmaceutical Strategies Group, accessed May 22, 2025, https://www.psgconsults.com/blog/exploring-the-2025-obesity-drug-pipeline/
20. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist - PMC, accessed May 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7526454/
21. A Study of LY3537031 in Overweight, Obese, and Healthy Participants - Lilly Trials, accessed May 22, 2025, https://trials.lilly.com/en-US/trial/533078
22. A Study of LY3537031 in Overweight, Obese, and Healthy Participants, accessed May 22, 2025, https://connect.careboxhealth.com/en-US/trial/listing/533078
23. accessed January 1, 1970, https://clinicaltrials.gov/study/NCT04648865
24. TrialScreen: Find and participate in medical research studies, accessed May 22, 2025, https://app.trialscreen.org/trials/phase-1-ly3537031-overweight-obese-healthy-participants-trial-nct06606106
25. A Study of LY3537031 in Overweight, Obese, and Healthy Participants - ClinicalTrials.Veeva, accessed May 22, 2025, https://ctv.veeva.com/study/a-study-of-ly3537031-in-overweight-obese-and-healthy-participants
26. accessed January 1, 1970, https://clinicaltrials.gov/study/NCT06606106
27. Dose Escalation Methods in Phase I Cancer Clinical Trials - PMC, accessed May 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2684552/
28. 1 Statistical Considerations When Planning Phase I Clinical Trials in Oncology - From the Safety Perspective （Early Considera - PMDA, accessed May 22, 2025, https://www.pmda.go.jp/files/000272425.pdf
29. US11918623B2 - GIP/GLP1 agonist compositions - Google Patents, accessed May 22, 2025, https://patents.google.com/patent/US11918623B2/en
30. Lilly Scientific Disclosures at Congress Events, accessed May 22, 2025, https://medical.lilly.com/us/science/conferences
31. Webcasts & Presentations | Eli Lilly and Company, accessed May 22, 2025, https://investor.lilly.com/webcasts-and-presentations
32. Welcome to Lilly Scientific Information Page for Obesity Week 2023, accessed May 22, 2025, https://medical.lilly.com/us/science/conferences/diabetes/ow
33. Obesity Week 2024 - Eli Lilly Medical Information, accessed May 22, 2025, https://medical.lilly.com/us/science/conferences/obesity/ow2024